JP2020138981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020138981A5 JP2020138981A5 JP2020100961A JP2020100961A JP2020138981A5 JP 2020138981 A5 JP2020138981 A5 JP 2020138981A5 JP 2020100961 A JP2020100961 A JP 2020100961A JP 2020100961 A JP2020100961 A JP 2020100961A JP 2020138981 A5 JP2020138981 A5 JP 2020138981A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- preparation according
- concentration
- antibody
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023030012A JP2023060016A (ja) | 2017-03-01 | 2023-02-28 | モノクローナル抗体製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465269P | 2017-03-01 | 2017-03-01 | |
| US62/465,269 | 2017-03-01 | ||
| JP2019547137A JP2020509025A (ja) | 2017-03-01 | 2018-02-28 | モノクローナル抗体製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547137A Division JP2020509025A (ja) | 2017-03-01 | 2018-02-28 | モノクローナル抗体製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030012A Division JP2023060016A (ja) | 2017-03-01 | 2023-02-28 | モノクローナル抗体製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020138981A JP2020138981A (ja) | 2020-09-03 |
| JP2020138981A5 true JP2020138981A5 (https=) | 2021-02-25 |
| JP7590125B2 JP7590125B2 (ja) | 2024-11-26 |
Family
ID=61868490
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547137A Pending JP2020509025A (ja) | 2017-03-01 | 2018-02-28 | モノクローナル抗体製剤 |
| JP2020100961A Active JP7590125B2 (ja) | 2017-03-01 | 2020-06-10 | モノクローナル抗体製剤 |
| JP2023030012A Pending JP2023060016A (ja) | 2017-03-01 | 2023-02-28 | モノクローナル抗体製剤 |
| JP2023034558A Pending JP2023071916A (ja) | 2017-03-01 | 2023-03-07 | モノクローナル抗体製剤 |
| JP2025014959A Pending JP2025072446A (ja) | 2017-03-01 | 2025-01-31 | モノクローナル抗体製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547137A Pending JP2020509025A (ja) | 2017-03-01 | 2018-02-28 | モノクローナル抗体製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030012A Pending JP2023060016A (ja) | 2017-03-01 | 2023-02-28 | モノクローナル抗体製剤 |
| JP2023034558A Pending JP2023071916A (ja) | 2017-03-01 | 2023-03-07 | モノクローナル抗体製剤 |
| JP2025014959A Pending JP2025072446A (ja) | 2017-03-01 | 2025-01-31 | モノクローナル抗体製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20200283516A1 (https=) |
| EP (2) | EP3797792A1 (https=) |
| JP (5) | JP2020509025A (https=) |
| KR (1) | KR102589598B1 (https=) |
| CN (2) | CN112057419B (https=) |
| AU (2) | AU2018227036B2 (https=) |
| BR (1) | BR112019018022A2 (https=) |
| CA (2) | CA3235178A1 (https=) |
| MX (1) | MX2019010282A (https=) |
| WO (1) | WO2018158332A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| HUE056580T2 (hu) | 2013-05-30 | 2022-02-28 | Kiniksa Pharmaceuticals Ltd | Onkosztatin-M-receptor antigénjét kötõ fehérjék |
| EP3088517B1 (en) | 2013-12-26 | 2023-11-01 | Mitsubishi Tanabe Pharma Corporation | Human anti-il-33 neutralizing monoclonal antibody |
| ES2795727T3 (es) | 2014-01-15 | 2020-11-24 | Medimmune Llc | Anticuerpos específicos del vrs y partes funcionales de los mismos |
| JP6799530B2 (ja) | 2014-10-01 | 2020-12-16 | メディミューン リミテッド | チカグレロルに対する抗体および使用方法 |
| JP6871948B2 (ja) | 2016-04-27 | 2021-05-19 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法 |
| TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| MX2019012255A (es) | 2017-04-11 | 2019-12-05 | Kiniksa Pharmaceuticals Ltd | Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr). |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| IL272864B2 (en) | 2017-08-31 | 2024-03-01 | Mitsubishi Tanabe Pharma Corp | Il-33 antagonist-containing therapeutic agent for endometriosis |
| CN120267817A (zh) * | 2018-09-14 | 2025-07-08 | 田边三菱制药株式会社 | 含有人抗il-33单克隆抗体的医药用组合物 |
| KR102880762B1 (ko) | 2018-09-20 | 2025-11-03 | 에스에프제이 파마 엑스, 인코포레이티드 | 티카그렐러 활성을 반전시키는 방법 |
| WO2020081408A1 (en) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| US12024553B2 (en) * | 2019-04-30 | 2024-07-02 | Medimmune Limited | Dosage regimens for and compositions including anti-RSV antibodies |
| WO2021188034A1 (en) * | 2020-03-17 | 2021-09-23 | Xbrane Biopharma Ab | Novel combination of tis sequence and signal peptide sequence for expressing a recombinant protein |
| JP2021147383A (ja) | 2020-03-23 | 2021-09-27 | メドイミューン・リミテッドMedImmune Limited | アトピー性皮膚炎及び関連障害を処置するための方法 |
| KR20230004489A (ko) | 2020-03-23 | 2023-01-06 | 메디뮨 리미티드 | 아토피 피부염 및 관련 장애의 치료 방법 |
| KR20220163447A (ko) * | 2020-04-06 | 2022-12-09 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체 제형 |
| JP7804590B2 (ja) * | 2020-05-11 | 2026-01-22 | メディミューン リミテッド | 抗ｉｌ－３３抗体の処方物 |
| GB202108379D0 (en) | 2021-06-11 | 2021-07-28 | Medlmmune Ltd | Methods for treating a topic dermatitis and related disorders |
| TW202325731A (zh) | 2021-08-16 | 2023-07-01 | 美商麥迪紐有限責任公司 | 抗ｉｌ—１３抗體調配物 |
| WO2023052408A1 (en) | 2021-09-28 | 2023-04-06 | Medimmune Limited | Methods for treating atopic dermatitis and related disorders |
| CN119095584A (zh) * | 2022-12-01 | 2024-12-06 | 天境生物科技(杭州)有限公司 | 抗gm-csf抗体的液体药物配制品及其用途 |
| WO2024190892A1 (ja) | 2023-03-16 | 2024-09-19 | 小野薬品工業株式会社 | 抗体製剤 |
| KR20250156121A (ko) | 2023-03-16 | 2025-10-31 | 오노 야꾸힝 고교 가부시키가이샤 | 항체 제제 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| MX2008012291A (es) * | 2006-03-27 | 2009-01-12 | Medimmune Ltd | Miembro que enlaza al receptor gm-csf. |
| CN101541345A (zh) * | 2006-09-25 | 2009-09-23 | 米迪缪尼有限公司 | 稳定化的抗体制剂和其应用 |
| CA2674608A1 (en) | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
| WO2009026122A1 (en) * | 2007-08-17 | 2009-02-26 | Amgen Inc. | Formulations of antibodies and fc-fusion molecules using polycations |
| WO2010106812A1 (en) * | 2009-03-19 | 2010-09-23 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical formulation containing improved antibody molecules |
| AR080428A1 (es) * | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| NZ602685A (en) * | 2010-03-01 | 2014-10-31 | Cytodyn Inc | Concentrated protein formulations and uses thereof |
| WO2012049278A1 (en) * | 2010-10-15 | 2012-04-19 | Medimmune Limited | Therapies for improving pulmonary function |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EP4527855A3 (en) | 2012-03-26 | 2025-06-11 | Sanofi | Stable igg4 based binding agent formulations |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| CN104768578A (zh) * | 2012-10-25 | 2015-07-08 | 米迪缪尼有限公司 | 稳定的低粘度抗体配制品 |
| AR093297A1 (es) * | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| CN107073113A (zh) * | 2014-10-18 | 2017-08-18 | 辉瑞大药厂 | 抗il‑7r抗体组合物 |
| TWI761453B (zh) * | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
-
2018
- 2018-02-28 BR BR112019018022-2A patent/BR112019018022A2/pt unknown
- 2018-02-28 WO PCT/EP2018/054960 patent/WO2018158332A1/en not_active Ceased
- 2018-02-28 US US16/488,302 patent/US20200283516A1/en not_active Abandoned
- 2018-02-28 KR KR1020197028472A patent/KR102589598B1/ko active Active
- 2018-02-28 CA CA3235178A patent/CA3235178A1/en active Pending
- 2018-02-28 AU AU2018227036A patent/AU2018227036B2/en active Active
- 2018-02-28 EP EP20190885.2A patent/EP3797792A1/en active Pending
- 2018-02-28 EP EP18714973.7A patent/EP3589318A1/en active Pending
- 2018-02-28 MX MX2019010282A patent/MX2019010282A/es unknown
- 2018-02-28 CN CN202010229368.0A patent/CN112057419B/zh active Active
- 2018-02-28 JP JP2019547137A patent/JP2020509025A/ja active Pending
- 2018-02-28 CA CA3054386A patent/CA3054386A1/en active Pending
- 2018-02-28 CN CN201880014493.0A patent/CN110366429B/zh active Active
-
2020
- 2020-06-10 JP JP2020100961A patent/JP7590125B2/ja active Active
-
2021
- 2021-04-07 US US17/224,900 patent/US20220089713A1/en not_active Abandoned
- 2021-09-29 AU AU2021240216A patent/AU2021240216A1/en not_active Abandoned
- 2021-11-19 US US17/455,713 patent/US20220204597A1/en not_active Abandoned
-
2023
- 2023-02-28 JP JP2023030012A patent/JP2023060016A/ja active Pending
- 2023-03-07 JP JP2023034558A patent/JP2023071916A/ja active Pending
-
2024
- 2024-05-28 US US18/676,425 patent/US20250163142A1/en active Pending
- 2024-12-10 US US18/976,239 patent/US20250333493A1/en active Pending
-
2025
- 2025-01-31 JP JP2025014959A patent/JP2025072446A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020138981A5 (https=) | ||
| US12049495B2 (en) | Stable protein solution formulation containing high concentration of an anti-VEGF antibody | |
| JP6416841B2 (ja) | 医薬製剤 | |
| JP7473603B2 (ja) | 液体医薬組成物 | |
| JP7046088B2 (ja) | 抗ｒｓｖモノクローナル抗体製剤 | |
| JP2020518599A5 (https=) | ||
| TWI857996B (zh) | 含高濃度抗ｖｅｇｆ抗體之蛋白質溶液配製物 | |
| JP2013500947A5 (https=) | ||
| JP2024160287A5 (https=) | ||
| JP2019509311A5 (https=) | ||
| JP2018076350A5 (https=) | ||
| JP2020509031A5 (https=) | ||
| JP2013543505A5 (https=) | ||
| JP2019504086A5 (https=) | ||
| JP2020532562A5 (https=) | ||
| JP2019501920A5 (https=) | ||
| JP2020511443A5 (https=) | ||
| JP2022519796A5 (https=) | ||
| JP2021501213A5 (https=) | ||
| CN111683681A (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
| JP2021533149A5 (https=) | ||
| JP2024513039A5 (https=) | ||
| CN116077650A (zh) | 一种稳定的新冠中和抗体的药物组合物及其应用 | |
| RU2025121573A (ru) | Стабильные белковые композиции антитела к pd1 | |
| JP2024538091A5 (https=) |